Welcome to our dedicated page for Riskified SEC filings (Ticker: RSKD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Chargeback guarantees, merchant concentration risk, and ever-evolving fraud patterns make Riskified’s SEC disclosures anything but straightforward. Hunting through a 10-K to find how much cash is reserved for chargeback liabilities—or which executives sold shares after a new algorithm launch—costs precious time.
Stock Titan solves this with AI-powered summaries that translate complex language into plain English. Whether you need the Riskified quarterly earnings report 10-Q filing broken down line by line or want instant alerts on Riskified insider trading Form 4 transactions, our platform delivers:
- Real-time feeds of every 8-K, 10-Q, 10-K, and proxy—plus Riskified Form 4 insider transactions real-time
- Plain-language explanations for cash-to-chargeback ratios, R&D spend on the risk engine, and revenue tied to gross merchandise value
- AI highlights that answer natural questions like “What drives Riskified’s guarantee liability?” and “How is merchant concentration disclosed?”
Looking for the next catalyst? Our engine tags key sections, so “Riskified 8-K material events explained” is just one click away. Need governance details? The latest Riskified proxy statement executive compensation is parsed, showing how leadership pay aligns with fraud-loss targets. And if you’re monitoring insider sentiment, the “Riskified executive stock transactions Form 4” dashboard keeps you updated before the market reacts.
From Riskified annual report 10-K simplified insights to concise Riskified earnings report filing analysis, Stock Titan turns dense disclosures into actionable intelligence—so you spend minutes, not hours, extracting what matters.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has furnished an 8-K under Item 7.01 to disclose positive interim Phase 2 results for its mRNA candidate ARCT-810, which is being developed to treat ornithine transcarbamylase (OTC) deficiency. The company states that the investigational therapy is designed to replace the OTC enzyme and restore urea-cycle function, thereby preventing hyperammonemia crises in affected patients.
- A press release detailing the data and a webcast presentation were released on 30 Jun 2025 and are attached as Exhibits 99.1 and 99.2.
- The disclosure is furnished—not filed—under Regulation FD; therefore, it carries no Section 18 liability and will not be incorporated by reference into future SEC filings.
- No financial statements, earnings figures, or transaction details are included.
The filing underscores continued progress in Arcturus’s rare-disease pipeline and may influence investor sentiment pending full Phase 2 data and eventual pivotal trials.
FAQ
What is the current stock price of Riskified (RSKD)?
What is the market cap of Riskified (RSKD)?
What does Riskified Ltd specialize in?
How does Riskified generate revenue?
What technology is central to Riskified's solution?
How does the chargeback protection guarantee work?
Which industries benefit from Riskified's services?
How does Riskified differentiate itself from competitors?
What are the main components of Riskified's business model?
How does Riskified enhance merchant and customer trust?
